Establishment of Sensitive Indexes System of Rational Application of Preventive Use of Proton Pump Inhibitors Constructed on Delphi Method

doi:10.16153/j.1002-7777.2022.06.013

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 698-704. DOI: 10.16153/j.1002-7777.2022.06.013

Xu Chi, Sun Zhonghua, Jiang Kai, Zhao Shanshan, Li Xiangcheng, Jia Xiuling

Author information +

History +

Abstract

Objective: To establish sensitive indexes for the rational application of preventive use of proton pump inhibitors. Methods: Through evidence-based and group discussion, the sensitivity index of rational application of preventive use of proton pump inhibitors was preliminarily established, the Delphi method was adopted to conduct 2 rounds of letter consultation for 27 pharmaceutical and medical inspectors respectively, and the results were statistically sorted out. Results: The constructed sensitive indexes for rational application of preventive use of proton pump inhibitors include 3 fi rst-level indexes, 8 second-level indexes and 17 thirdlevel indexes. The effective recovery rates of 2 rounds of expert letter consultation were 90% and 100%. The authoritative coeffi cients of second rounds were 0.80, and the overall coordination coeffi cient was 0.352, which were statistically significant (P＜0.01). Conclusion: The constructed sensitive index of rational application of preventive use of proton pump inhibitors has certain credibility, which could provide an objective and quantifi able evaluation tool for management and evaluation of the rational application of preventive use of proton pump inhibitors.

Key words

PPI； sensitive indexes system； Delphi method； rational use of drugs

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Xu Chi, Sun Zhonghua, Jiang Kai, Zhao Shanshan, Li Xiangcheng, Jia Xiuling. Establishment of Sensitive Indexes System of Rational Application of Preventive Use of Proton Pump Inhibitors Constructed on Delphi Method[J]. Chinese Pharmaceutical Affairs, 2022, 36(6): 698-704 https://doi.org/10.16153/j.1002-7777.2022.06.013

References

[1] 广东省药学会.预防性使用质子泵抑制剂及处方精简专家指导意见[J].今日药学,2019,29(8):505-514.
[2] 陈静,陈世才,刘洋,等.骨科患者围术期使用质子泵抑制药预防应激性溃疡的现状分析[J].中国临床药理学杂志,2020,36(7):860-862.
[3] 邢晓璇,褚燕琦,冯于洛,等.围术期使用抑酸药预防应激性溃疡的临床应用现状及PPIs安全性认知度的多中心问卷调查[J].药物流行病学杂志,2018,27(11):733-738.
[4] 张拥军,郭曙光,方健,等.住院患者质子泵抑制剂使用合理性分析[J].中国药业,2017,26(21):82-84.
[5] 白荷荷,聂晓静,王金萍,等.住院患者预防使用质子泵抑制剂的合理性评价[J].临床药物治疗杂志,2017,15(7):30-34.
[6] Minalyan A,Gabrielyan L,Scott D,et al.The Gastric and Intestinal Microbiome:Role of Proton Pump Inhibitors[J].Curr Gastroenterol Rep,2017,19(8):42.
[7] 郑松柏,姚健风.老年人质子泵抑制剂合理应用专家共识[J].中华老年医学杂志,2015,34(10):1045-1052.
[8] Dearholt S L,Dang D.Johns-hopkinsNursing Evidencebased Practice:Model and Guidelines[M].Second Edition.Indianapolis:Sigma Theta Tau International,2012.
[9] 张华芳,冯志仙,邵乐文,等.护理质量敏感性指标的构建[J].中华护理杂志,2015,50(3):287-291.
[10] 严莉,文进,陈永琴,等.基于改良德尔菲法和复杂网络模型的肿瘤护理质量敏感指标构建[J].中国卫生质量管理,2020,27(5):55-58.
[11] Wilson S,Hauck Y,Bremner A,et al.Quality Nursing Care in Australian Pediatric Hospitals:A Delphi Approach to Identifying Indicators[J].Journal of Clinical Nursing,2012,21(11/12):1594-1605.
[12] 徐驰,贾秀玲,范静,等.静脉用药调配中心静脉输液安全质量敏感指标构建[J].护理学杂志,2019,34(16):62-64.
[13] 匡国芳,吕世慧,于鹏,等.卵巢肿瘤患者护理质量敏感指标体系的构建[J].中华现代护理杂志,2020,26(26):3634-3638.
[14] 李思琴,涂双燕,汪莉,等.脑卒中护理过程指标应用的研究进展[J].护理研究,2020,34(13):2329-2333.
[15] 盛丽乐,兰星,谭芳,等.麻醉后监护室护理质量敏感指标的构建[J].中华护理杂志,2020,55(6):805-810.
[16] Stalpers D,Kieft RAMM,Van der Linden D,et al.Concordance between Nurse-reported Quality of Care and Quality of Care as Publicly Reported by Nurse-sensitive Indicators[J].BMC Health Serv Res,2016,16:120.
[17] 刘鑫鑫.以Donabedian结构—过程—结果理论构建儿科护理敏感性质量指标评价体系[D].杭州:浙江大学出版社,2017.
[18] 陈珺仪,席淑新,石美琴.德尔菲法在专科护理质量评价指标研究中的应用现状[J].护理研究,2016,30(29):3591-3595.
[19] 丁玲,芦鸿雁,路露.老年患者出院计划风险筛查指标的构建[J].护理学杂志,2018,33(21):5-8.
[20] 张清华,金锐,王琨,等.基于循证药学的处方前置审核系统在门诊药房中的实践与探讨[J].中国医院药学杂志,2020,40(4):443-447.
[21] 王仲萍,徐萌欣.静脉用药集中调配中心临床药师医嘱前置审核工作模式的探索[J].黑龙江医学,2020,44(2):226-228.
[22] 吕晓峰,张迪,边有鑫.住院药房推行医嘱审核药学服务制度的效果与价值探讨[J].中国药业,2016,25(20):86-88.
[23] 黄雅菲,俞平.我院质子泵抑制剂预防应激性溃疡的合理性管控[J].海峡药学,2020,32(2):191-194.
[24] Guda N M,Noonan M,Kreiner M J,et al.Use of Intravenous Proton Pump Inhibitors in Community Practice:An Explanation for the Shortage[J].Am J Gastroenterol,2004,99(7):1233-1237.
[25] Murie J,Allen J,Simmonds R,et al.Glad You Brought It Up:A Patient-centred Programme to Reduce Protonpump Inhibitor Prescribing in General Medical Practice[J].Qual Prim Care,2012,20(2):141-148.
[26] Thompson W,Hogel M,Li Y,et al.Effect of a Proton Pump Inhibitor Deprescribing Guideline on Drug Usage and Costs in Long-term Care[J].J Am Med DirAssoc,2016,17(7):673.